Show Notes
Can higher doses of semaglutide really deliver better results, without the side effects? In this episode of Docs Who Lift, Dr. Spencer Nadolsky and Dr. Karl Nadolsky Jr. sit down with Canadian obesity expert and clinical trialist Dr. Sean Wharton to break down the latest data from the STEP-UP trial. They dig into the science behind tripling the dose of semaglutide, how it compares to drugs like tirzepatide, and what it means for the future of obesity treatment.
More from Docs Who Lift
Dr. Ken Custer, President of Lilly's Cardiometabolic Health, joins Dr. Spencer Nadolsky and Dr. Karl Nadolsky for the first big pharma executive interview in Docs Who Lift history. He breaks down the new retatrutide and eluralintide data out of EASD, why Lilly bet on a selective amylin agonist, what drug development actually costs, and where pricing and access are headed.
Obesity researchers Dr. David Allison and Dr. Emily Dhurandhar explain how they defined and built a validated questionnaire for food noise, the persistent and distressing thoughts about food that many patients say disappear on GLP-1 medications. They break down how food noise differs from hunger and cravings, where the research is going next, and why the term came from patients, not pharmaceutical companies.
Dr. Christian Rodriguez unpacks his review on metabolically healthy obesity, showing why the concept is mostly a temporary phase rather than a stable protective state. He and the hosts compare the new Lancet Commission obesity criteria against the ACE staging system, then debate GLP-1 stigma and the ethics of treating obesity before it turns severe.
Is severe, insatiable hunger a failure of willpower or hardcoded into your biology? In this episode of Docs Who Lift, Dr. Spencer and Dr. Karl Nadolsky speak with obesity specialist Dr. Jesse Richards to uncover Bardet-Biedl Syndrome (BBS), the updated 2024 diagnostic criteria, and how targeted therapies offer hope when standard GLP-1s and willpower aren't enough.
Dr. Spencer Nadolsky and Karl sit down with Dr. Susan Brian to break down one of the most significant proposed changes in women's health in decades, the potential renaming and reclassification of polycystic ovarian syndrome to anovulatory androgen excess, and what that shift means for the millions of women who have been diagnosed, misdiagnosed, or dismissed under the current framework.